Company News: Agena Bioscience Announces Expanded Partnership with Assurex Health
– MassArray® System Selected for Assurex Health’s GeneSight Test
Agena Bioscience today announced that Assurex Heath, a wholly owned subsidiary of Myriad Genetics, Inc., has selected the MassARRAY® System for streamlined laboratory set-up and sample processing of Assurex Health’s GeneSight test.
The GeneSight Psychotropic test helps clinicians select appropriate medications for patients with depression and other mental health conditions by analyzing how a patient’s genetic make-up will impact the patient’s response to different psychotropic medications.
Assurex Health initially selected the MassARRAY System for its laboratory-developed test because it provides a robust, simple, highly cost-effective workflow resulting in faster time-to-result and greater capacity for the laboratory. To date, Assurex Health has run over 150,000 GeneSight tests using the MassARRAY System. Going forward under the new partnership, Assurex Health expects to significantly increase the number of GeneSight test samples run on the platform.
“Agena Bioscience is passionate about providing affordable multiplex molecular systems to laboratories worldwide to help them significantly expand access to clinically relevant genomic data. Pharmacogenomics testing is a foundational application in the sweet spot for targeted genetic analysis on our MassARRAY System. We are proud to be chosen by Assurex Health, and see the partnership as a significant accelerator into this clinical market segment,” said Pete Dansky, Chief Executive Officer at Agena Bioscience.
The MassARRAY System enables high-throughput, accurate detection of SNPs, INDELs, and copy number variations across a variety of genetic applications. The flexibility and scalability of the platform facilitate easy development of custom panels and validation across large numbers of samples.
Assurex Health Vice President, Laboratory Operations, Sandra Gunselman, Ph.D. commented, “The GeneSight test has seen tremendous adoption and growth, with hundreds of thousands of patients tested. We are committed to providing our customers with rapid turnaround time and scalability that enables us to meet the ever-growing demand for the test. With fewer touch points and less variability in workflow, our team can continue to accelerate service to psychiatrists and their patients.”
The GeneSight Psychotropic test is supported by five published clinical studies demonstrating its efficacy and cost effectiveness. For more information visit www.genesight.com.